Peripheral nerve injury is accompanied by chronic transcriptome-wide changes in the mouse prefrontal cortex

Sebastian Alvarado1,2†, Maral Tajerian3,4†, Magali Millecamps4,5, Mathew Suderman1,2, Laura S Stone1,3,4,5,6 and Moshe Szyf1,2*

Abstract

Background: Peripheral nerve injury can have long-term consequences including pain-related manifestations, such as hypersensitivity to cutaneous stimuli, as well as affective and cognitive disturbances, suggesting the involvement of supraspinal mechanisms. Changes in brain structure and cortical function associated with many chronic pain conditions have been reported in the prefrontal cortex (PFC). The PFC is implicated in pain-related co-morbidities such as depression, anxiety and impaired emotional decision-making ability. We recently reported that this region is subject to significant epigenetic reprogramming following peripheral nerve injury, and normalization of pain-related structural, functional and epigenetic abnormalities in the PFC are all associated with effective pain reduction. In this study, we used the Spared Nerve Injury (SNI) model of neuropathic pain to test the hypothesis that peripheral nerve injury triggers persistent long-lasting changes in gene expression in the PFC, which alter functional gene networks, thus providing a possible explanation for chronic pain associated behaviors.

Results: SNI or sham surgery were performed in male CD1 mice at three months of age. Six months after injury, we performed transcriptome-wide sequencing (RNAseq), which revealed 1147 differentially regulated transcripts in the PFC in nerve-injured vs. control mice. Changes in gene expression occurred across a number of functional gene clusters encoding cardinal biological processes as revealed by Ingenuity Pathway Analysis. Significantly altered biological processes included neurological disease, skeletal muscular disorders, behavior, and psychological disorders. Several of the changes detected by RNAseq were validated by RT-QPCR and included transcripts with known roles in chronic pain and/or neuronal plasticity including the NMDA receptor (glutamate receptor, ionotropic, NMDA; grin1), neurite outgrowth (roundabout 3; robo3), gliosis (glial fibrillary acidic protein; gfap), vesicular release (synaptotagmin 2; syt2), and neuronal excitability (voltage-gated sodium channel, type I; scn1a).

Conclusions: This study used an unbiased approach to document long-term alterations in gene expression in the brain following peripheral nerve injury. We propose that these changes are maintained as a memory of an insult that is temporally and spatially distant from the initial injury.

Keywords: Neuropathic pain, Chronic pain, RNA sequencing, Transcriptome, Noncoding RNA, Neuronal plasticity

* Correspondence: moshe.szyf@mcgill.ca
† Equal contributors
1 Department of Pharmacology and Therapeutics, McGill University, Faculty of Medicine, 3655 Promenade Sir William Osler, Montréal, Québec H3G 1Y6, Canada
2 Sackler Program for Epigenetics & Developmental Psychobiology, McGill University, 3655 Promenade Sir William Osler, Montréal, Québec H3G 1Y6, Canada
Full list of author information is available at the end of the article

© 2013 Alvarado et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Peripheral nerve injury can result in a multitude of changes within an organism, including motor dysfunction, pain and associated cognitive and emotional comorbidities. While acute pain related to an injury is protective and normally resolves, chronic pain can be detrimental to the overall wellbeing and functioning of the individual. Indeed, occasionally the “memory” of injury, in the form of chronic pain, persists long after the initial recovery phase and becomes difficult to reverse. This is due, in part, to changes in anatomy and function that take place in the peripheral as well as the central nervous system. These changes can occur at many levels: individual molecules, synapses, cellular function, and network activity [1]. It is therefore not surprising that injury is often accompanied by local or systemic alterations in gene expression. To date, several reports have identified strong links between injury and transcriptional changes in the peripheral nervous system [2], blood [3] and in the brain [4]. However, the full profile of transcriptional changes that accompany chronic pain in response to peripheral injury is unknown.

The fact that peripheral injury results in chronic behavioral changes suggests that transient exposure to injury is chronically embedded in the transcription programming within the central nervous system, resulting in altered phenotypic behaviors. In the current study, we tested this hypothesis by focusing on the transcriptional changes that occur in the prefrontal cortex (PFC) of chronically neuropathic mice six months after the induction of neuropathy. This area was chosen based on evidence indicating its involvement in pain modulation [5,6] and epigenetic differences that accompany peripheral nerve injury [7]. In humans with back pain, reversible pathological changes in both cortical thickness and functional activation have been shown in the PFC [8]. In animal models of neuropathic pain, the PFC undergoes synaptic re-organization as early as 8 days following nerve injury [9], and shows reductions in grey matter 5 months post-injury [10]. Since the PFC has also been implicated in depression and anxiety [11], common co-morbidities of chronic pain, transcriptional changes in brain regions such as the PFC can also provide an explanation for these co-morbidities.

While brain-specific transcription associated with neuropathic pain and injury has been previously investigated, few studies have looked at the effects at time points longer than ~1 month post-injury, whereas individual patients often suffer for many years following the initial injury. This distinction is critical as the development of co-morbid conditions, such as anxiety-like behavior in the rat, takes multiple months to develop [10]. Thus, early time points might not fully incorporate the impact of long term chronic pain on CNS plasticity. Furthermore, previous studies have been limited by microarray-based technologies that are inherently biased by probe density/design and limited to coding mRNA transcripts [12]. We therefore investigated the long-term (6 months post-injury) transcriptional changes induced by peripheral injury in the prefrontal cortex using whole transcriptome sequencing (RNAseq) in a mouse model of chronic pain (Spared Nerve Injury, SNI). Furthermore, we employed bioinformatic tools to identify functional gene clusters that were altered in the prefrontal cortex.

The aim of this work is to provide a comprehensive and unbiased look at the molecular correlates of peripheral nerve injury and catalog long-term transcriptional changes that may play a role in the pathologies associated with injury and pain. We believe that our findings will help shed light on the “signature” of painful neuropathy in the brain at both the molecular and network levels.

Results
Peripheral injury is accompanied by behavioral signs of neuropathic pain six months post-injury
The persistence of nerve injury-induced hypersensitivity to mechanical and cold stimuli and injury-related motor impairment were confirmed six months following SNI (data not shown; mechanical thresholds (grams) = 0.20±0.05 in SNI vs 0.82±0.07 in controls, p<0.0001; acetone-evoked behaviors (seconds) = 2.9±0.4 vs. 0.4±0.05 in controls, p<0.0001; motor impairment (latency to fall from accelerating rotarod) = 76±11 in SNI vs. 225±21 in controls, p<0.0001; n=10/group).

Peripheral injury is accompanied transcriptomic changes in the prefrontal cortex six months post-injury
Six months following SNI, significant changes in the expression levels of 1147 different transcripts were identified in the prefrontal cortex (Figure 1, Additional file 1: Table S1). Considering the genomic base pair representation of exonic (3.2%), intronic (35.5%) and intergenic (61.3%) elements in mouse (Figure 1A), the PFC SNI-associated transcriptome was equally partitioned between coding RNA accounting for 40% (exonic) and 60% non-coding (intergenic+intronic) base pairs of the transcriptome (Figure 1B). Within differentially expressed transcripts in SNI vs. sham control animals, the largest transcriptional changes were observed in protein-coding exons (63.4%) with the rest made up of non-coding RNA. Within non-coding RNAs, the largest observed changes were in non-translated transcripts (retained introns and processed transcripts) followed by classes of microRNAs, transcribed processed pseudogenes, lincRNAs and nonsense mediated decay (Figure 1C).

The transcripts with the largest log2 fold changes in RNA expression in response to SNI (summarized in Table 1) included several transcripts with previously uncharacterized
roles in the brain. Within this subset, specific transcripts with a role in subcellular structure (actbl, coll1a2, krt12, krt20) and development pathways (lrat [13], aldha3al [14], crbl [15]) show some of the greatest transcriptional changes. These transcripts showed large transcriptional differences from control ranging between 4.20 and 5.20 log2fold change.

We further classified differentially expressed transcripts in SNI animals that have brain-specific functions (Summarized in Table 2). Examples include down-regulation of neurotransmitter channel and receptor subunits gabrg1/3, clca1, slc14a1 and drd2 and the astrocyte marker gfap while sodium channel subunit scn1a, NMDA subunit grn1, and promoters of neuronal growth xlr4b, robo3, prc, and cux1 were all up-regulated in PFC from injured mice. Specific transcripts identified with asterisks in Tables 1 and 2 were further validated with RT-qPCR (labeled with asterisks) and summarized in Figures 2A-D, 3B-C, 4B-C and 5B. Within these validated genes, robo3, scn1a, grn1, xlr4b, krt20, syt2, and lbp showed marked induction following SNI while gfap and clca1 showed marked repression (unpaired 2-tailed t-test, p<0.05, n=8). Whereas the genes in Figure 2 were selected for validation due to an interesting role in the CNS, Figures 4, 5, and 6 highlight validated genes within the context of an identified functional gene cluster.

Peripheral nerve injury results in changed brain-specific transcriptional programs

Ingenuity Pathway Analysis (IPA) identified specific networks that were dysregulated six months post-SNI in the prefrontal cortex. Biological functions with a cutoff p-value < 0.05 were considered statistically significant. We identified the following biological functions specific to peripheral nerve injury: neurological disease (p-value=2.02E-21-1.46E-02), behavior (p-value=2.68E-12-1.31E-02), psychological disorder (p-value=7.80E-11-1.46E-02), protein synthesis (p-value=1.70E-10 to 4.23E-03), and nervous system development and function (p-value=5.93E-10 to 1.42E-02) (Figure 6, Additional file 2: Table S2). In our screen, genetic disorders and skeletal muscular disorders emerged but due to an unclear role in CNS we did not perform further validation within these pathways.

With each biological function comprised of hundreds of functional gene clusters we then focused on transcriptional clusters previously associated with neurological function. Within this scope, peripheral injury resulted in up-regulation of pathways involved in cellular growth and proliferation (Figure 3A), molecular transport and neurological disease (Figure 4A) and neuronal development (Figure 5A). We validated the induction of representative genes included in these clusters by QT-PCR: robo3 and krt20 in the cellular growth and proliferation pathway (Figure 3B-C), scn1a and syt2 in the molecular transport and neurological disease pathway (Figure 4B-C) and grin1 in the neuronal development pathway (Figure 5B).

Discussion

Our results delineate for the first time a transcriptomic signature in the prefrontal cortex resulting from peripheral injury six months prior. Interestingly, both coding and non-coding transcripts are altered.

The coding transcripts include both genes that were previously implicated in the pathology associated with neuronal plasticity as well as genes with yet an unknown role in brain function, neuronal plasticity or in chronic pain. We further mapped the functional gene pathways whose transcription was altered, identified specific clusters involved in neuronal plasticity and validated candidate genes within these pathways. Genes known to play a role in brain structure and function that were differentially expressed and validated in response to peripheral injury were: clca1, syt2, grin1, scn1a, krt20, xlr4b, gfap,
## Table 1: Top upregulated and downregulated transcripts in SNI

| Gene                                           | Chr | Start             | End               | p-Value       | Log₂fold change |
|------------------------------------------------|-----|-------------------|-------------------|---------------|-----------------|
| Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 | 5   | 145036642         | 145036834         | 1.23E-08      | -5.20           |
| A330050B17Rik                                   | 3   | 35921194          | 35924028          | 5.37E-07      | -4.92           |
| Actin, beta-like 2                              | 13  | 112045221         | 112047957         | 8.12E-10      | -4.56           |
| mmu-mir-220                                     | 6   | 13634896          | 136349031         | 5.54E-20      | -4.53           |
| Crumbs homolog 1                                | 1   | 141142194         | 141145652         | 4.49E-5       | -4.43           |
| Collagen, type XI, alpha 2                      | 17  | 34189110          | 34189163          | 2.34E-4       | -4.23           |
| Thyrotropin-releasing hormone receptor          | 15  | 44065008          | 44065236          | 2.34E-4       | -4.22           |
| Gm14204                                        | 2   | 158421208         | 158422248         | 1.10E-12      | -4.08           |
| Gap junction alpha-5                           | 3   | 96879570          | 96881313          | 2.37E-11      | 5.60            |
| Keratin 20*                                    | 11  | 99299001          | 99299464          | 7.97E-6       | 4.65            |
| Mediator complex subunit 23                    | 10  | 24589792          | 24589952          | 4.30E-4       | 4.08            |
| Keratin 12                                     | 11  | 99280858          | 99281014          | 3.83E-10      | 4.08            |
| 40S ribosomal protein S28                     | 17  | 33959981          | 33960061          | 1.47E-13      | 3.76            |
| A830036E02Rik                                   | 11  | 99283179          | 99283574          | 1.77E-17      | 3.69            |
| Lecithin-retinol acyltransferase                | 3   | 82696501          | 82701050          | 4.22E-08      | 3.10            |
| Thiosulfate sulfurtransferase (rhodanese)-like domain containing 2 | 4   | 46151364          | 46151566          | 5.24E-4       | 2.77            |
| Complement component 1 r subcomponent A        | 6   | 124463670         | 124463895         | 5.24E-4       | 2.73            |
| Aldehyde dehydrogenase 3 family member A1      | 11  | 61028052          | 61028260          | 3.22E-6       | 2.61            |

Changes are labeled as log₂fold change.

## Table 2: Biased upregulated and downregulated transcripts in SNI with known brain-specific functions

| Gene                                           | Chr | Start             | End               | p-Value       | Log₂fold change |
|------------------------------------------------|-----|-------------------|-------------------|---------------|-----------------|
| Calcium-activated chloride channel regulator 1* | 3   | 144409728         | 144409992         | 4.95E-04      | -3.19           |
| Solute carrier family 14 (urea transporter), member 1 | 18  | 78308093          | 78308285          | 2.90E-06      | -2.37           |
| Gamma-aminobutyric acid receptor subunit gamma-1 | 5   | 71185588          | 71185952          | 8.00E-05      | -2.17           |
| Activating transcription factor 3               | 1   | 192994175         | 192995558         | 8.97E-7       | -1.98           |
| Fatty acid binding protein 7                    | 10  | 57505312          | 57505484          | 4.36E-12      | -1.44           |
| Gamma-aminobutyric acid receptor subunit gamma-3 | 7   | 64433752          | 64435107          | 3.29E-04      | -1.38           |
| Glial fibrillary acidic protein *               | 11  | 102753225         | 102753268         | 2.40E-4       | -1.24           |
| Fos                                            | 12  | 86816542          | 86816649          | 4.62E-04      | -0.90           |
| Dopamine receptor D2                            | 9   | 49215006          | 49216282          | 1.44E-05      | -0.88           |
| X-linked lymphocyte-regulated 4B *              | X   | 70463702          | 70467280          | 1.72E-03      | 3.87            |
| Lipopolysaccharide-binding protein*             | 2   | 158139209         | 158139364         | 3.31E-04      | 2.54            |
| Protein regulator of cytokinesis 1             | 7   | 87460000          | 87461144          | 5.70E-05      | 2.40            |
| Cut-like homeobox 1                             | 5   | 137041250         | 137041567         | 1.46E-04      | 2.24            |
| Roundabout, axon guidance receptor, homolog 3* | 9   | 37227254          | 37227393          | 1.51E-05      | 1.96            |
| Sodium channel, voltage-gated, type I, alpha subunit* | 2   | 66166462          | 66166603          | 4.34E-04      | 1.10            |
| Synaptotagmin-2*                                | 1   | 13664052          | 136649726         | 9.10E-09      | 0.91            |
| Synapsin 1                                      | X   | 20497359          | 20498130          | 1.72E-03      | 0.59            |
| Glutamate [NMDA] receptor subunit zeta-1*       | 2   | 25174149          | 25174615          | 3.31E-04      | 0.57            |

Changes are labeled as a log₂fold change.
Considering the importance of the PFC to chronic pain and its associated co-morbidities, these broad, functionally-relevant changes in the transcriptome of the PFC provides a possible substrate for the long-term systemic effects of peripheral injury and may elucidate transcriptional mechanisms of supraspinal pathologies associated with chronic pain.

Coding/noncoding transcriptomic changes

While annotated coding transcripts account for about a third (n=209000) of the long-term differential transcriptome in response to SNI, the remaining differentially-expressed transcripts were non-coding unannotated RNA (intergenic+intronic) (n=435000) (Figure 1B). Within differential exonic transcripts, we further classified all annotated genes into their respective RNA classes (Figure 1C). Approximately 60% of exonic elements represent protein-coding genes and the remaining 40% demonstrate a wide array of noncoding RNA with a previously uncharacterized role in peripheral nerve injury (Additional file 1: Table S1).

The role of noncoding RNA has been discussed extensively [16,17] and it is known to be involved in a variety of functions ranging from translation [18], splicing [19] to transcriptional regulation [20]. The fact that SNI induces non-coding (both annotated and un-annotated) transcripts in the brain that could be detected long after the initial injury suggests that they might be playing a functional role in the brain response to peripheral injury. However, the mechanisms involved remain unknown at this stage. Nevertheless, our data provide further support to the emerging idea that genome-function in the brain involves more than the commonly studied protein coding gene sequences.

Annotated SNI-associated transcriptional differences were categorized into biological functions using ingenuity pathway analysis and we identified statistically significant affected gene pathways pertinent to neurological disease, behavior and psychological disorders (Figure 6 Additional file 2: Table S2). The SNI-associated transcriptome of the PFC appears particularly relevant to several of the
co-morbidities associated with peripheral nerve injury such as poor sleep, anxiety and depression [21] as the PFC is highly implicated in these conditions [22-24]. Considering the identified molecular pathways (Figure 6), chronic neuropathic pain may alter higher order biological functions that may mediate these behavioral disorders.

Genes involved in chronic injury and altered neuronal growth and proliferation in the PFC

The up-regulation of robo3, krt20, xlr4b in response to peripheral injury and overall pathway analysis suggests altered regulation of gene networks involved in neuronal cellular growth (Figures 2 & 3, Additional file 2: Table S2). Previous work using the same model of peripheral nerve injury reported altered neuronal growth in injured animals characterized by longer basal dendrites with more branches in cortical layer 2/3 pyramidal neurons in injured vs. control animals [9]. The cell adhesion membrane protein ROBO3, which is up-regulated in the injured mice, has been shown to be essential for axonal guidance in drosophila [25] and is a regulator of cortical interneuron growth in mice [26] and serotonergic neuronal differentiation [27]. While not previously considered in the context of peripheral injury, its role in regulating morphology and function of neurons is consistent with a possible contribution to cortical remodeling in response to injury (Figure 3B).

xlr4b, a non-coding RNA, has been shown to regulate chromatin remodeling as well as modulate cognitive defects in a mouse model of Turner’s Syndrome [28]. Upstream regulators of xlr4b, cux1 and cux2 control the number and maturity of dendritic spines in cortical neurons in cortical layer 2/3 pyramidal neurons [29]. Interestingly, in addition to xlr4b, cux1 is up-regulated (4 fold) in the SNI animals, supporting the hypothesis that this gene regulatory pathway is activated (Additional file 1: Table S1 and Figure 3A). clca1, which is down-regulated in the PFC in response to peripheral nerve injury (Figure 2A), encodes a calcium chloride channel. Calcium chloride channels are highly conserved structurally but have diverse expression patterns and physiological functions [30,31]. CLCA1 has been implicated in neuronal death [32], suggesting that CLCA1 might play role in neuronal reorganization in the PFC.

Lastly, while krt20 is not directly implicated in neuronal growth, as a soft keratin and intermediary filament, its expression is ubiquitous. krt20 is up-regulated in the PFC (Figure 3C) in response to peripheral nerve injury and it is considered a member of functional pathways involved in cell cycle and proliferation (IPA analysis). Taken together, these data are consistent with alterations...
in regulation of cell growth and proliferation as a chronic response to peripheral nerve injury. However, direct experiments need to test whether these transcriptional changes in the PFC are causally involved in altering neuronal or associated cell growth in the PFC.

Molecular transport and neurological disease
Chronic pain changes the brain at various levels: changes in cortical grey matter [33,34], white matter [35], and overall cortical excitability [36] have all been reported. Recent studies have shown that chronic pain is linked to changes in synaptic structure and function in the primary somatosensory cortex [37], hippocampus [38], and anterior cingulate cortex [39]. It is therefore not surprising that several neurological disorders are co-morbid with chronic pain. Previous reports have shown chronic pain is associated with impaired decision-making [40], anxiety, depression and sleep disorders [41]. In the SNI model, the PFC exhibits signs of damage following peripheral injury [9,10]. Considering that the PFC is shown to regulate higher order emotional processing, transcriptional changes in the PFC can identify putative candidates mediating known co-morbid pathologies seen with chronic injury and/or pain.

Mutations in sodium channels have been previously implicated in pain and in the modulation of neuropathic and inflammatory pain [42,43]. In the present study, IPA-identified pathways reveal that the gene encoding sodium channel \( scn1a \), which is a member of the neurological disease functional gene cluster, is up-regulated in the SNI group (Figure 4C). Familial missense mutations in \( scn1a \) have been linked to epilepsy [44], migraines [45] and brain structure in aging individuals [46]. Interestingly, these familial missense mutations can result in increased sodium channel activity; for example, the D188V mutation (linked to epilepsy) results in impaired inactivation, and the Q1489K mutation (linked to familial hemiplegic migraine) results in changes in channel gating which include accelerated recovery from inactivation and increased persistent current [47]. Thus, the functional result of these missense mutations may be analogous to the impact of nerve injury-induced up-regulation of the same channel.

This is the first demonstration of long-term over-expression of \( scn1a \) in the prefrontal cortex following

**Figure 5 Cell cycle and growth.** SNI causes distinct changes in transcription in pathways involved in cell cycle and growth. (A) RNA sequencing and IPA identified interacting networks affecting cell cycle, cellular growth and proliferation and cellular development. Upregulated transcripts are marked with red while downregulated transcripts are marked in blue. ROBO3 (B) and KRT20 (C) transcripts were validated by qPCR. *=p<0.05. n=8/group. Error bars = S.E.M.
peripheral injury. Nevertheless, our data is consistent with previous reports showing up-regulation of SCN3A, for example, in dorsal root ganglia following axotomy [48]. The data is consistent with the hypothesis that scn1a overexpression (and to a lesser degree scn1b, scn2b, and scn4b (Additional file 1: Table S1)) is involved in increased cortical excitability [49] associated with chronic pain.

**Synaptotagmin II** (syt2) is up-regulated in our model in response to peripheral injury (Figure 3B) which is consistent with its role in neurological function and disease. Synaptotagmins are Ca2+ sensors involved in vesicular trafficking and exocytosis and mediate vesicular release important for neurotransmission [50]. Syt2 was previously reported to be involved in vesicular GABAergic transmission [51], and may therefore also be involved in pain-mediated alterations in GABA and glutamate receptor activation known to accompany models of peripheral injury [52].

LBP, a mediator of innate immunity [53], is up-regulated in the PFC of animals with peripheral nerve injury. Interestingly, LBP-KO mice show increased spine density and abnormal spine morphology, indicating a role for LBP role in synaptic pruning [54]. We speculate that its role in TLR4 signaling may link it to the neuroinflammation and depression induced by treatment with lipopolysaccharide [55]. Altered LBP expression in the PFC in response to SNI might be playing similar roles in the gene networks, possibly mediating cortical neuroinflammation in animals with peripheral nerve injury.

**Nervous system development and function**

One of the functional gene pathways that is highly enriched by genes that are differentially expressed six months after nerve injury is the pathway involved in nervous system development and function (Figure 5, Additional file 2: Table S2). One member of this cluster which is up-regulated by SNI is **grin1** (NMDA receptor subunit 1). NMDA receptors are linked to neuroplastic changes including long-term potentiation [56] and implicated in psychiatric disorders [57-59] and anxiety [60,61].

Within the nervous system development and function cluster we found a marked decrease in the expression of **gfap**, a marker for astrocytes. Astrocytes are implicated in synapse maintenance, secretion of neurotrophins, and overall function in maintaining neuroplasticity. Previous work has shown that peripheral nerve injury is associated with increased levels of **gfap** in the spinal and medullary dorsal horns [62,63], anterior cingulate cortex [64-66], and the periaqueductal gray, during early and intermediate time points after injury [65]. However, there is evidence...
showing gla is down-regulated in the PFC in psychological disorders [67,68]. Furthermore, pain-related pathological changes in neuroinflammation in the spinal cord, such as microglial activation, may occur in the absence of parallel dysregulation in supraspinal structures [69], and glial activation following spinal cord injury is both spatially and temporally regulated. Thus, the well documented increases in astrocyte activation in the spinal cord following nerve injury [70] may not be mirrored in the PFC and/or gla could be up-regulated during the early and middle stages of injury but down-regulated at very chronic stages once the co-morbidities have appeared.

Conclusions
We demonstrate broad changes in gene expression in the mouse prefrontal cortex six months after peripheral nerve injury, illustrating a long-term impact of a peripheral injury on brain genome function. The use of RNAseq allowed for an unbiased picture of the transcriptomic changes involved in chronic neuropathy in the PFC. Furthermore, the ingenuity pathway analysis revealed functional gene networks that were significantly implicated including networks involved in brain development and function. These reported changes and their functional analysis will generate hypotheses on the molecular mechanisms that mediate chronic pain and its co-morbidities that will need to be tested in future experiments.

These wide-spread changes in gene expression in the PFC are consistent with our previous report demonstrated significant genome-wide changes in global DNA methylation that we predicted would result in the dysregulation of hundreds of genes. Thus, epigenetic mechanisms that embed the transient peripheral injury into a long-term programmatic change in gene function in the brain may be contribution to these mechanisms [7].

Although we demonstrate a causal relationship between peripheral injury and a transcriptome change six months later, it is unknown whether these are the same changes that occurred in the brain at the time of injury or whether (and more probably) a cascade of gene expression alterations led to the chronic profile observed in our study. Furthermore, it is unknown if similar changes occur in other spinal or supraspinal regions. Further experiments are required at multiple time point and in additional brain regions, including those not implicated in pain signaling, before the significance of these findings can be fully understood. Finally, there is currently no evidence that these patterns are the cause of chronic pain or its associated co-morbidities. Nevertheless, our study strongly supports the plausibility that long-term changes in gene expression in the CNS are involved in chronic pain and its associated behaviors, and generates hypotheses on the genes and functional gene networks that might be involved.

Methods
Animals
8–10 week-old male CD1 mice (Charles River, St-Constant, QC, Canada) were used. Animals were housed in ventilated polycarbonate cages and received water and standard laboratory rodent diet (Harlan Teklad, soy-free diet 2020X ad libitum. All experiments were approved by the Animal Care Committee at McGill University, and conformed to the ethical guidelines of the Canadian Council on Animal Care and the guidelines of the Committee for Research and Ethical Issues of the International Association for the Study of Pain published in PAIN, 16 (1983) 109–110. All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering.

Induction of nerve injury
Neuropathy was induced using the spared nerve injury model. Under deep anesthesia, an incision was made on the lateral surface of the thigh through the muscle, exposing the three terminal branches of the sciatic nerve: the sural, common peroneal and tibial nerves. The common peroneal and the tibial nerves were tightly ligated with 6.0 silk (Ethicon) and sectioned distal to the ligation. The sural nerve was left intact. Sham surgery involved exposing the nerve without damaging it [71,72].

Behavioral assessment
Mechanical sensitivity
Calibrated monofilaments (Stoelting Co., Wood Dale, IL) were applied to the plantar surface of the hindpaw and the 50% threshold to withdraw (grams) was calculated as previously described [73]. The stimulus intensity ranged from 0.008 g to 4 g.

Cold sensitivity
A modified version of the acetone drop test [74] was used: total duration of acetone evoked behaviors (flinching, licking or biting) was measured for 1 minute after acetone (~25 μl) was applied to the plantar surface of the hindpaw.

Motor function
The accelerating rotarod assay was used (IITC Life Science Inc., Woodland Hills, CA) with the mouse adapter [75]. The task includes a speed ramp from 0 to 30 rpm over 60 s, followed by an additional 240 s at the maximal speed.

Tissue extraction
Animals were sacrificed 6 months after nerve injury or sham surgery by decapitation following isoflurane anesthesia. Anatomical regions were defined according to the stereotaxic coordinates (rostral–caudal, mediolateral and dorsal–ventral from bregma) by Paxinos and Franklin [76]. The prefrontal cortex (right and left; +1 to
+3, -1 to +1, 0 to -2.5) was extracted, frozen on dry ice and stored at −80°C until use.

RNA extraction and RNA sequencing
RNA was extracted with Trizol (Invitrogen) according to the manufacturer’s protocol and treated with DNase. cDNA libraries and RNA sequencing was performed by Genome Quebec on the Illumina Genome Analyzer IIX following Illumina guidelines.

Expression validation
3 ug of RNA was used for cDNA conversion using random hexamers (Roche Molecular Biochemicals) according to manufacturer’s guidelines. Expression primers were designed over overlapping exons with Autoprime.de [77] or specific to single exons that were differentially expressed in RNAseq and are shown in Additional file 3: Table S3. All reactions for all subjects (n=6-8 per group) were performed on the LightCycler 480 (Roche) in triplicate and statistical significance was determined as P<0.05 using one-tailed t-tests. Quantitative PCR was amplified with a pre-incubation at 95°C for 10 minutes followed by 45 cycles of [95°C for 10 seconds, 60°C for 10 seconds, 72°C for 10 sec] followed by 10 minutes of 72°C. Expression was measured relative to GAPDH expression, which demonstrated stable unchanged expression from RNAseq results.

RNAseq analysis
Two animals were sequenced per condition with 36 bp reads with single end sequencing. RNAseq reads were aligned to the genome (mm9) using Top Hat [59,78]. Between 36 and 40 million reads aligned to unique genomic locations. Differential expression was determined from read counts per transcript, exon and 1000 bp genomic partition using Bioconductor [79] package DESeq [80] with default parameter settings. Transcript annotations were obtained from Ensembl version 63.37 (http://www.ensembl.org/). Concordance of read counts per 1000bp genomic partition between pairs of samples ranged between 0.88 to 0.99.

Pathway analysis
Ingenuity Software was used to perform whole pathway analysis in the identification of affected networks and their relationship to each other based on the differential expression between SNI and Sham treated mice. Briefly, our data set containing gene identifiers and corresponding expression values was uploaded into the application. Each identifier was mapped to its corresponding object in the Ingenuity Knowledge Base. Differentially expressed genes, called Network Eligible molecules, were overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. Networks of Network Eligible Molecules were then algorithmically generated based on their connectivity. Pathways presented were chosen from following candidate gene validation (as indicated with asterisks in Table 2). Right-tailed Fisher’s exact test was used to calculate a p-value determining the probability that each pathway, biological function and/or disease assigned to that data set is due to chance alone.

Additional files

Additional file 1: Table S1. List of differentially regulated genes as revealed by RNAseq.

Additional file 2: Table S2. Ingenuity Pathway Analysis of altered biological functions in Sham vs. SNI PFC.

Additional file 3: Table S3. QPCR primer sets used for validation.

Abbreviations
CLCA1: Calcium-activated chloride channel regulator 1; CNS: Central nervous system; GFAP: Gial fibrillary acidic protein; GRN: T: Glutamate receptor, ionotropic, N-methyl D-aspartate 1; IPA: Ingenuity pathway analysis; KRT20: Keratin 20; LBP: Lipopolysaccharide binding protein; PCR: Polymerase chain reaction; PFC: Prefrontal cortex; RNAseq: RNA sequencing; ROBO3: Roundabout, axon guidance receptor, homolog 3; SCN1A: Sodium channel, voltage-gated, type I, alpha subunit; SNi: Spared nerve injury; SYT2: Synaptotagmin II; XLR4B: X-linked lymphocyte-regulated 48.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SA and MT Overall experimental design, collecting the mouse behavioral data, performing RNA data collection and analysis and drafting the manuscript. MM Induction of nerve injury, collection of brain tissue Suderman: Bioinformatics analysis of RNAseq data. All reactions of the experiments, supervision of the experiments and writing of the manuscript. AS and MT Overall experimental design, collecting the mouse behavioral data, performing RNA data collection and analysis and drafting the manuscript. Szyf: Overall design of the experiments and writing of the manuscript. LSS Overall design of the experiments, supervision of the experiments and writing of the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
This work was funded by CIHR MOP-102586 and a FRSQ bourse de chercheur-boursier to LSS, a gift to the Sackler McGill Program in Psychobiology and Epigenetics (MS) and a grant from the Canadian Institute for Advanced Research (MS). MT was supported by a studentship from The Louise and Alan Edwards Foundation.

Author details
1Department of Pharmacology and Therapeutics, McGill University, Faculty of Medicine, 3655 Promenade Sir William Osler, Montréal, Québec H3G 1Y6, Canada. 2Sackler Program for Epigenetics & Developmental Psychobiology, McGill University, 3655 Promenade Sir William Osler, Montréal, Québec H3G 1Y6, Canada. 3Department of Neurology and Neurosurgery, McGill University, Faculty of Medicine, 3801 University Street, Montreal, Quebec H3A 1A4, Canada. 4Faculty of Dentistry, McGill University, 3640 University Street, Montreal, Quebec H3A 2B4, Canada. 5Alan Edwards Centre for Research on Pain, McGill University, 740 Dr. Penfield Avenue, Montreal, Quebec H3A 1A4, Canada. 6Department of Anesthesiology, Anesthesia Research Unit, McGill University, Faculty of Medicine, 3655 Promenade Sir William Osler, Montreal, Quebec H3G 1Y6, Canada.

Received: 3 December 2012 Accepted: 22 March 2013 Published: 18 April 2013

References
1. Kuner R: Central mechanisms of pathological pain. Nat Med 2010, 16:1258–1266.
2. Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu G, Xu SH, et al: Identification of gene expression profile of dorsal root ganglion...
in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci USA 2002, 99:8380–8385.

3. Grace PM, Hurley D, Barratt DT, Tsukin A, Watkins LR, Rolan PE, Hutchinson MR: Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model. J Neurochem 2012, 122:576–594.

4. Poh KW, Yeo JF, Stohler CS, Ong WY: Comprehensive gene expression profiling in the prefrontal cortex links immune activation and neutrophil infiltration to antinociception. J Neurosci 2012, 32:35–45.

5. Tracey I, Bushnell MC: How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain 2009, 10:1113–1120.

6. Schweinhardt P, Bushnell MC: Pain imaging in health and disease–how far have we come? J Clin Invest 2010, 120:3788–3797.

7. Tajerian M, Alvarado S, Millecamps M, Vachon P, Crosby C, Bushnell MC, Szyf M, Stone LS: Peripheral nerve injury is associated with chronic, reversible changes in global DNA methylation in the mouse prefrontal cortex. PLoS One 2013, 8:e55259.

8. Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA, Jacrem P, Bushnell MC, Shir Y, Ouellet JA, Stone LS: Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J Neurosci 2011, 31:7540–7550.

9. Metz AE, Yau HJ, Centeno MV, Apkarian AV, Martina M: Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci USA 2009, 106:2423–2428.

10. Seminowicz DA, Laforterre AL, Millecamps M, Yu JS, Coddere TJ, Bushnell MC, MR: Structural brain changes associated with sensory and emotional function in a rat model of long-term neuropathic pain. Neuroimage 2009, 47:1007–1014.

11. Augustinsson LE, Sullivan L, Sullivan M: Physical, psychologic, and social function in chronic pain patients after epidural spinal electrical stimulation. Spine (Phila Pa 1976) 1986, 11:111–119.

12. Metzler ML: Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:93–103.

13. Batten ML, Imanishi Y, Maeda T, Tu DC, Moise AR, Bronson D, Posin D, Van Gelder RN, Baehr W, Palczewski K: Lecithin-retinol acyltransferase is essential for accumulation of all-trans-retinyl esters in the eye and in the liver. J Biol Chem 2004, 279:10422–10432.

14. Shiao T, Tran P, Siegel D, Lee J, Visvillo Y: Four amino acid changes are associated with the ADR3a1 locus polymorphism in mice which may be responsible for core mal sensitivity to ultraviolet light. Pharmacogenet Genomics 1999, 9:145–153.

15. Bulgakova NA, Knust E: The Cumbys complex: from epithelial-cell polarity to retinal degeneration. J Cell Sci 2009, 122:2578–2596.

16. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Jensen JC, Trapnell C, Jeddeloh JA, Freeman BV, Tenenbaum HC, Davis KD: Abnormal gray matter aging in chronic pain patients. Brain Res 2012, 1456:82–93.

17. Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA, Jacrem P, Bushnell MC, Shir Y, Ouellet JA, Stone LS: Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J Neurosci 2011, 31:7540–7550.

18. Wilson BA, Masel J: Putatively noncoding transcripts show extensive association with ribosomes. Genome Biol Evol 2011, 3:1245–1252.

19. Kishore S, Stamm S: The snoRNA H1B1-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006, 313:230–232.

20. Yao MJ, Chen G, Zhao PP, Lu MH, Jian J, Liu MF, Yuan XB: The role of Robo3 in the development of cortical interneurons. Cereb Cortex 2009, 19(Suppl 1):1222–31.

21. Couch JA, Chen J, Reff HI, Uri EM, Condron BC: robo2 and robo3 interact with eagle to regulate serotonergic neuron differentiation. Development 2004, 131:997–1006.

22. Raffaeli AS, O’Neill MJ: Identification of a cluster of X-linked imprinted genes in mice. Nat Genet 2005, 37:520–524.

23. Cubillos B, Sebastian-Serrano A, Beccari L, Calcagnotto ME, Cisneros E, Kim S, Dompao A, Alves-Dolado M, Redondo M, Bouvillain P, et al: Clux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layers of the cortex. Neuron 2010, 66:523–535.

24. Drummond SP, Brown GG, Gillin JC, Stricker JL, Wong EC, Buxton RB: Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-D-aspartate receptors. Neuroscience 2009, 158:342–348.

25. Maysey M, Weissman-Fogel I, Salamons TV, Crawley AP, Goldberg MB, Freeman BV, Tenenbaum HC, Davis KD: Abnormal gray matter aging in chronic pain patients. Brain Res 2012, 1456:82–93.

26. As-Sanie S, Harris RE, Nadapowd V, Kim J, Neshewat G, Kairys A, Williams D, Clauw DJ, Schmidt-Wilcke T: Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain 2012, 153:1006–1014.

27. Szabo N, Kincses ZT, Pardutz A, Tajti J, Szak D, Tuka B, Kishlay A, Babos M, Voros E, Bomboi G, et al: White matter microstructural alterations in migraine: a diffusion-weighted MRI study. Pain 2012, 153:651–656.

28. Li W, Dui S, An J, Li P, Chen X, Xiong R, Liu P, Wang H, Zhao Y, Zhu M, et al: Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 2008, 151:1198–1207.

29. Kim SK, Nabekura J: Rapid synaptic remodeling in the adult somatosensory cortex following peripheral nerve injury and its association with neuropathic pain. J Neurosci 2011, 31:5477–5482.

30. Kim SK, Eto K, Nabekura J: Synaptic structure and function in the mouse somatosensory cortex during chronic pain: in vivo two-photon imaging. Neural Plast 2012, 2012:640259.

31. Eto K, Wake H, Watanabe M, Ishibashi H, Noda M, Yanagawa Y, Nabekura J: Inter-regional contribution of enhanced activity of the primary somatosensory cortex to the anterior cingulate cortex accelerates chronic pain behavior. J Neurosci 2011, 31:7631–7636.

32. Apkarian AV, Sosa Y, Krauss BR, Thomas PS, Fredrickson BE, Levy RE, Harden RN, Chalvov DR: Chronic pain patients are impaired on an emotional decision-making task. Pain 2004, 108:129–136.

33. Gore M, Sadowsky A, Stacey MC, Raat K, Leslie D: The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine (Phila Pa 1976) 2012, 37:E668–E77.

34. Liu M, Wood JN: The roles of sodium channels in nociception: Implications for mechanisms of neuropathic pain. Pain Med 2011, 12(Suppl 3):593–99.

35. Dib-Haj SiD, Cummins TR, Black JA, Waxman SG: Sodium channels in normal and pathological pain. Ann Rev Neurosci 2010, 33:255–345.

36. Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, Moulard B, Clagne D, et al: Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000, 24:343–345.

37. Dichtgans M, Freiling T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM, Pusch M, Strom TM: Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005, 366:371–377.

38. Meier S, Demirakca T, Bruniski W, Liebsch K, Tunc-Sarka N, Nieratschker V, Witt SH, Matthaus F, Ende G, et al: SCN1A Affects Brain Structure and the Neural Activity of the Aging Brain. Biol Psychiatry 2012, 72:677–683.

39. Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen R, Rugiero F, Wood JN: Neurological perspectives on voltage-gated sodium channels. Brain 2012, 135:2585–2612.

40. Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG: Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci 2004, 24:4832–4839.
49. Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB, Rubenstein JL, Catterall WA: Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 2012, 109(14):5666–5671.

50. Petrova A, Perin MS, Davletov BA, Ushkaryov YA, Geppert M, Sudhof TC: Binding of synaptophysin to the alpha-latrotoxin receptor implicates both in synaptic vesicle exocytosis. Nature 1991, 353:65–68.

51. Bragina L, Fattorini G, Giovedi S, Melone M, Bosco F, Benfenati F, Conti F: Analysis of Synaptophysin, SV2, and Rab3 Expression in Cortical Glutamatergic and GABAergic Axon Terminals. Front Cell Neurosci 2011, 5:32.

52. Ji G, Neugebauer V: Pain-related deactivation of medial prefrontal cortical neurons involves mGlur1 and GABA(A) receptors. J Neurophysiol 2011, 106:2642–2652.

53. Muta T, Takeshige K: Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR2) as well as TLR4 Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur J Biochem 2001, 268:4850–4859.

54. Wei L, Simen A, Mane S, Kaffman A: Brain-derived neurotrophic factor-activated astrocytes produce mechanical allodynia in neuropathic pain.

55. Garate I, Garcia-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR, Mico JA, Leza JC: Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011, 8:151.

56. Chen PE, Errington ML, Kneussel M, Chen G, Annala AJ, Rudhard YH, Rast GF, Specht CG, Tigert CM, Nassar MA, et al: Behavioral deficits and subregion-specific suppression of LTP in mice expressing a population of NMDA receptors throughout the hippocampus. Learn Mem 2009, 16:635–644.

57. Sakurai K, Toru M, Yamakawa-Kobayashi K, Arinami T: Glutamatergic and GABAergic Axon Terminals. Neuroscience 2000, 296:168–170.

58. Tarabeux J, Keber O, Gauthier J, Hamdan FF, Xiong L, Pittor A, Spiegelman D, Henrion E, Millet B, Fathalli F, et al: Rare mutations in N-methyl-D-aspartate receptor NR1 subunit (GRIN1) in nonsyndromic intellectual disability. Am J Hum Genet 2011, 88:306–316.

59. Labrie V, Clapcote SJ, Roder JC: Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol Biochem Behav 2009, 91:610–620.

60. Furuse T, Wada Y, Hattori K, Yamada I, Kuzin R, Shibukawa Y, Masuya H, Kaneda H, Miura I, Seno N, et al: Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis. Eur J Neurosci 2010, 31:1281–1291.

61. Zhang X, Wang J, Zhou Q, Xu Y, Pu S, Wu J, Xue Y, Tian Y, Lu J, Jiang W, Du D: Brain-derived neurotrophic factor-activated astrocytes produce mechanical allodynia in neuropathic pain. Neurosci Lett 2011, 499:452–460.

62. Piao ZG, Cho HK, Park CK, Hong JP, Choi SY, Lee SJ, Lee S, Park K, Kim JS, Oh SB: Activation of glia and microglia p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 2006, 121:219–231.

63. Chen FL, Dong YL, Zhang ZJ, Cao DL, Xu J, Hui J, Zhu L, Gao YJ: Activation of astrocytes in the anterior cingulate cortex contributes to the affective component of pain in an inflammatory pain model. Brain Res Bull 2012, 875:66–70.

64. Lu Y, Zhu L, Gao YJ: Pain-related aversion induces astrocytic reaction and proinflammatory cytokine expression in the anterior cingulate cortex in rats. Brain Res Bull 2011, 84:178–182.

65. Kuzumaki N, Naita M, Hareyama N, Nikura K, Nagumo Y, Nocai H, Arimoto T, Suzuki T: Chronic pain-induced astrocyte activation in the cingulate cortex with no change in neural or glial differentiation from neural stem cells in mice. Neurosci Lett 2007, 415:22–27.

66. Miguel-Hidalgo JL, Walter R, Whitcomb AA, Austin MC, Rajkowska G, Stockmeier CA: Gial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 2010, 127:230–240.

67. Alvarado et al.: Molecular Pain 2013, 9:21

Cite this article as: Alvarado et al.: Peripheral nerve injury is accompanied by chronic transcriptome-wide changes in the mouse prefrontal cortex. Molecular Pain 2013 9:21.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit